Elotuzumab therapy for relapsed or refractory multiple myeloma

Keyphrases

• Relapsed or Refractory multiple Myeloma 100%
• Elotuzumab 100%
• Lenalidomide 36%
• Progression-free Survival 27%
• Overall Response Rate 18%
• Disease Risk 9%
• Hazard Ratio 9%
• Confidence Interval 9%
• Pneumonia 9%
• Disease Progression 9%
• Adverse Events 9%
• Progression Rate 9%
• Phase II Study 9%
• Relative Reduction 9%
• Interim Analysis 9%
• Neutropenia 9%
• Median Progression-free Survival 9%
• Infusion Reaction 9%
• Signaling Lymphocyte Activation Molecule 9%
• Lymphocytopenia 9%
• Immunomodulatory Antibodies 9%
• Antibody Targeting 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Myeloma 100%
• Elotuzumab 100%
• Lenalidomide 36%
• Progression Free Survival 36%
• Dexamethasone 36%
• Adverse Event 9%
• Monoclonal Antibody 9%
• Disease Exacerbation 9%
• Neutropenia 9%
• Signaling Lymphocytic Activation Molecule 9%
• Lymphocytopenia 9%